Skip to main navigation
Skip to search
Skip to main content
Johns Hopkins University Home
Home
Profiles
Research units
Research output
Search by expertise, name or affiliation
The use of omalizumab in allergen immunotherapy
J. A. Dantzer
,
R. A. Wood
School of Medicine
Research output
:
Contribution to journal
›
Review article
›
peer-review
49
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'The use of omalizumab in allergen immunotherapy'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Pharmacology, Toxicology and Pharmaceutical Science
Immunotherapy
100%
Allergen
100%
Omalizumab
100%
Asthma
30%
Placebo
10%
Adverse Event
10%
Randomized Controlled Trial
10%
Immunoglobulin E
10%
Erethism
10%
Chronic Urticaria
10%
Peanut
10%
Allergic Rhinitis
10%
Food Allergy
10%
Pollen Allergy
10%
Allergy
10%
Immunology and Microbiology
Allergen Immunotherapy
100%
Omalizumab
100%
Immunotherapy
40%
Asthma
30%
Immunoglobulin E
10%
Medline
10%
Hypersensitivity
10%
Chronic Urticaria
10%
Allergen
10%
Pollen Allergy
10%
Allergic Rhinitis
10%
Food Allergy
10%
Allergy
10%
Keyphrases
Venom Hypersensitivity
10%